Home » Stocks » ABOS

Acumen Pharmaceuticals, Inc. (ABOS)

Acumen Pharmaceuticals will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
Market Cap n/a
Revenue (ttm) n/a
Net Income (ttm) -32.28M
Shares Out n/a
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day n/a
Last Price n/a
Previous Close n/a
Change ($) n/a
Change (%) n/a
Day's Open n/a
Day's Range n/a
Day's Volume n/a
52-Week Range n/a

News

Acumen Pharmaceuticals, Inc. has filed to go public with an IPO on the NASDAQ.

1 week ago - SEC

About ABOS

Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what we believe to be a key underlying cause of Alzheimer’s disease, or AD. Based on decades of research and supporting evidence, soluble amyloid-beta oligomers, or AbOs have gained increasing scientific acceptance as a primary toxin involved in the initiation and propagation of AD pathology. We are currently focused on advancing a targeted immunotherapy drug candidate, ACU193, and establishing proof of mechanism in ear... [Read more...]

Industry
Biological Products
IPO Date
Pending
CEO
Daniel O’Connell
Employees
7
Stock Exchange
NASDAQ
Ticker Symbol
ABOS
Full Company Profile

Financial Performance

Financial Statements